{"id":"placebo-to-match-asenapine","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos contain no active pharmaceutical ingredient and serve as control comparators in randomized controlled trials. This specific placebo is formulated to match asenapine (an atypical antipsychotic) in appearance, taste, and administration route to maintain blinding in phase 3 trials, allowing researchers to isolate the true therapeutic effect of asenapine from placebo response.","oneSentence":"This is an inert placebo formulation designed to match the physical and sensory characteristics of asenapine for blinded clinical trial comparisons.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:49.203Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control comparator in phase 3 clinical trials of asenapine"}]},"trialDetails":[{"nctId":"NCT00212784","phase":"PHASE3","title":"Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-09-04","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":1225},{"nctId":"NCT01098110","phase":"PHASE3","title":"6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-05-25","conditions":"Schizophrenia","enrollment":532},{"nctId":"NCT01244815","phase":"PHASE3","title":"Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-06-16","conditions":"Bipolar Disorder, Pediatric","enrollment":404},{"nctId":"NCT01617187","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-12-04","conditions":"Schizophrenia","enrollment":360},{"nctId":"NCT00150176","phase":"PHASE3","title":"To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-04","conditions":"Schizophrenia","enrollment":831},{"nctId":"NCT03565068","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-20","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT03319953","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2017-12-21","conditions":"Stable Schizophrenia","enrollment":23},{"nctId":"NCT02181803","phase":"PHASE1","title":"MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-05","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT01396291","phase":"PHASE3","title":"Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-12","conditions":"Bipolar 1 Disorder","enrollment":561},{"nctId":"NCT01670019","phase":"PHASE4","title":"Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression","status":"COMPLETED","sponsor":"Duke University","startDate":"2012-10","conditions":"Major Depressive Disorder Without Psychotic Features","enrollment":46},{"nctId":"NCT01684657","phase":"PHASE3","title":"A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering","status":"SUSPENDED","sponsor":"University of California, Irvine","startDate":"2012-09","conditions":"Stuttering","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to match asenapine","genericName":"Placebo to match asenapine","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is an inert placebo formulation designed to match the physical and sensory characteristics of asenapine for blinded clinical trial comparisons. Used for Control comparator in phase 3 clinical trials of asenapine.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}